文献速递艾滋病与性传播感染

多替拉韦/拉米夫定用于有拉米夫定耐药史者维持病毒学抑制:单臂开放标签多中心IIa期试验48周结果

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该单臂、开放标签、多中心IIa期试验纳入病毒学抑制、有拉米夫定耐药史(经基因型确认或临床怀疑)、无整合酶耐药且CD4+>200细胞/mm3的HIV感染者,基线前病毒DNA群体测序未检出M184V/I者换用多替拉韦/拉米夫定。48周时4例(3.3%,95%CI:0.9%-8.2%)HIV-1 RNA≥50拷贝/mL,未见治疗 emergent 整合酶耐药。

要点

  • 基线前病毒DNA群体测序排除M184V/I后,多替拉韦/拉米夫定维持病毒学抑制有效。
  • 48周病毒载量≥50拷贝/mL者4例(3.3%,95%CI:0.9%-8.2%)。
  • 未观察到治疗 emergent 整合酶耐药。

核心结论

  • 在通过群体测序排除前病毒DNA中的拉米夫定突变后,多替拉韦/拉米夫定在有拉米夫定耐药史、CD4+>200细胞/mm3的HIV感染者中有效维持病毒学抑制。
  • 值得注意的是,未观察到治疗 emergent 耐药。

研究设计与样本

  • 开放标签、单臂、多中心IIa期临床试验。
  • 纳入病毒学抑制、有拉米夫定耐药史(经基因型检测确认或基于临床病史怀疑)、无整合酶耐药且CD4+>200细胞/mm3的HIV感染者,基线前病毒DNA群体测序未检出M184V/I者换用多替拉韦/拉米夫定。
  • 共入组121例参与者,其中114例有既往基因型显示M184V/I,平均病毒学抑制9年。
  • 对基线样本回顾性进行前病毒DNA下一代测序(NGS)。

主要发现

  • 24例(19.8%)在基线前病毒DNA NGS中检出M184V/I(>5%阈值)。
  • 48周时,4例参与者HIV-1 RNA≥50拷贝/mL(3.3%,95%CI:0.9%-8.2%,FDA-Snapshot ITT-e):1例确认病毒学退出、1例预防性病毒学退出、2例因其他原因停止研究治疗且末次病毒载量≥50拷贝/mL。
  • 上述4例基线前病毒DNA NGS均未检出M184V/I,且未出现整合酶耐药。
  • 90.1%参与者(109/121)病毒载量<50拷贝/mL(95%CI:83.3%-94.8%),48周时6.6%(8/121)参与者无数据。

临床怎么用

  • 作者结论认为,在通过群体测序排除前病毒DNA中的拉米夫定突变后,多替拉韦/拉米夫定可有效维持有拉米夫定耐药史且CD4+>200细胞/mm3的HIV感染者的病毒学抑制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment for people with human immunodeficiency virus (HIV, PWH) and previous lamivudine resistance. METHODS: Open-label, single arm, multicentric clinical trial including virologically suppressed PWH with historical lamivudine resistance (confirmed by genotypic testing or suspected based on clinical history), no integrase resistance and CD4+ >200 cells/mm3 whose antiretroviral therapy (ART) was changed to dolutegravir/lamivudine if the M184V/I mutation was not detected in baseline proviral DNA population sequencing. Proviral DNA next-generation sequencing (NGS) was retrospectively performed in baseline samples. Primary endpoint was proportion of participants with huma immunodeficiency virus type 1 (HIV-1) RNA viral load (VL) ≥50 copies/mL at 48 weeks in the intention-to-treat-exposed (ITT-e) population using the Food and Drug Administration snapshot algorithm. RESULTS: In total, 121 participants enrolled, 114 with a prior genotype with M184V/I, mean virological suppression of 9 years. And 24 (19.8%) had the M184V/I in baseline proviral DNA NGS (>5% threshold). At 48 weeks, 4 participants had a VL ≥50 copies/mL (3.3%, 95% confidence interval [CI]: ·.9%-8.2%, FDA-Snapshot ITT-e): 1 confirmed virologic withdrawal, 1 precautionary virologic withdrawal, and 2 discontinued from study treatment for other reasons with last VL ≥50 copies/mL; none had M184V/I in baseline proviral DNA NGS, and there was no emergent integrase resistance. Also, 90.1% participants (109/121) had a VL <50 copies/mL (95% CI: 83.3%-94.8%), and there were no data for 6.6% (8/121 participants) at 48 weeks. CONCLUSIONS: After excluding lamivudine mutations in proviral DNA by population sequencing, dolutegravir/lamivudine effectively maintained virological suppression in PWH with CD4+ >200 cells/mm3 and history of lamivudine resistance. Notably, no treatment-emergent resistance was observed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. De Miguel R, de Lagarde Sebastian M, Blanco Arévalo JL, et al. Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial. Clin Infect Dis. 2025. PMID: 40052565. doi:10.1093/cid/ciaf100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。